{"id":"5dd7224a-4372-444b-a68d-b12f9a1ec4c4","modelId":"894204d2-44c2-4f9e-9261-5d64481f866a","versionId":null,"locationId":"0b7f16f7-9f8c-4105-b458-f98c50d360ef","operatorId":"bc532371-0bd2-47c6-9edc-7f5f701b2a24","ownerId":null,"slug":"parker-indego-atlanta-georgia-usa","status":"operational","firstSeen":"2014-09-01T00:00:00.000Z","statusChangeReason":null,"contractType":null,"pilotOutcome":null,"endedAt":null,"unitsOnSite":null,"tasksPerformed":null,"shiftStructure":null,"hoursPerDay":null,"siteType":null,"operatorConfirmed":null,"humanSupervisionOnsite":null,"locationPrecisionTier":null,"deploymentScale":null,"siteEnvironment":null,"operatorType":null,"sourceQualityTier":null,"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://investors.parker.com/news-events/press-releases/detail/190/fda-clears-parkers-indego-exoskeleton-for-clinical","label":"FDA Clears Parker's Indego Exoskeleton for Clinical, Personal Use","title":"FDA Clears Parker's Indego Exoskeleton for Clinical, Personal Use","mediaType":"article","sourceName":"Parker Hannifin Investor Relations","publishedAt":"2014-09-01"}],"notes":"Shepherd Center in Atlanta served as Parker's lead clinical partner for Indego testing and training. Over 1,200 individual sessions conducted with no serious adverse events.","keyFacts":[],"reviewNote":null,"exposureHours":null,"deploymentMilesEstimate":null,"exposureBasis":null,"customerSegment":null,"scaleTier":null,"contractValueUsd":null,"contractValueBasis":null,"customerCompanyId":null,"customerExternalName":null,"createdAt":"2026-08-15T09:04:50.865Z","updatedAt":"2026-08-17T04:53:26.877Z","model":{"id":"894204d2-44c2-4f9e-9261-5d64481f866a","companyId":"bc532371-0bd2-47c6-9edc-7f5f701b2a24","modelName":"Indego","slug":"parker-indego","description":"Parker Hannifin's Indego is a powered lower-limb exoskeleton, FDA-cleared via 510(k) in 2016, intended to enable individuals with spinal cord injury at levels T7 to L5 to perform ambulatory functions with supervision of a specially trained companion.","formFactor":"exoskeleton","industryVertical":null,"environment":null,"maturityStage":"research","lifecycleState":"active","supersededByModelId":null,"specs":{"class":"powered lower-limb exoskeleton","clearance":"FDA 510(k) 2016","indication":"SCI T7-L5"},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.southcarolinablues.com/web/public/brands/medicalpolicy/external-policies/powered-exoskeleton-for-ambulation-in-patients-with-lower-limb-disabilities/","sourceName":"Parker Hannifin / Indego"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"keyFacts":[{"label":"Form factor","value":"powered lower-limb exoskeleton"},{"label":"Clearance","value":"FDA 510(k) 2016"},{"label":"Indication","value":"SCI T7-L5"}],"createdAt":"2026-06-24T07:16:07.432Z","updatedAt":"2026-08-16T04:14:17.537Z","unitsInFieldClaimed":null,"unitsInFieldVerified":null,"unitsManufacturedClaimed":null,"unitsManufacturedVerified":null,"unitsAsOf":null,"unitsSource":null,"salesModel":null,"priceUndisclosedSince":null,"autonomyClass":null,"autonomyStatement":null,"autonomyStatementSource":null,"demoForensics":null,"exportControlClass":null,"minCommitment":null,"warrantyTerms":null,"serviceModel":null,"productionRateClaimed":null,"productionRateEvidenced":null,"teleopRatioDisclosed":null,"interventionRateDisclosed":null,"company":{"id":"bc532371-0bd2-47c6-9edc-7f5f701b2a24","name":"Parker Hannifin Indego","slug":"parker-hannifin-exoskeleton","description":"Parker Hannifin Indego was a division of Parker Hannifin that developed the Indego powered lower-limb exoskeleton for individuals with spinal cord injuries. Licensed from Vanderbilt University in 2012, the device received FDA clearance in March 2016 and CE Mark in November 2015, enabling users to stand and walk for up to four hours. Parker Hannifin sold the Indego business to Ekso Bionics in December 2022 for $10 million, exiting the exoskeleton market.","status":"active","founded":2012,"hq":"Cleveland, OH, USA","hqLat":41.4996574,"hqLng":-81.6936772,"hqGeocodedAt":"2026-08-05T14:43:06.985Z","hqAddress":null,"hqPrecision":null,"website":null,"fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.indego.com/","title":"Indego","date_accessed":"2026-06-07"}],"keyFacts":[{"label":"Robot","value":"Powered lower limb exoskeleton for rehabilitation and personal use"},{"label":"Products","value":"Indego Therapy and Indego Personal"},{"label":"Parent","value":"Parker Hannifin Corporation (NYSE: PH)"},{"label":"Product","value":"Indego — powered lower-limb exoskeleton"},{"label":"Use case","value":"Spinal cord injury rehabilitation, mobility assistance"},{"label":"CEO","value":"Tom Williams (Chairman & CEO of Parker Hannifin)"},{"label":"Business unit head","value":"Achilleas Dorotheou (VP, Human Motion and Control)"},{"label":"CTO","value":"Mark Czaja (Chief Technology and Innovation Officer)"},{"label":"Technology origin","value":"Licensed from Vanderbilt University (2012)"},{"label":"FDA clearance","value":"March 2016"},{"label":"CE Mark","value":"November 2015"},{"label":"Acquired by","value":"Ekso Bionics (December 2022, $10M)"},{"label":"DOD study funder","value":"CDMRP/SCIRP (4-year multi-center study)"},{"label":"Clinical trial","value":"Largest US exoskeleton clinical trial, 1,200+ sessions, no serious adverse events"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-06-08T04:05:18.726Z","updatedAt":"2026-08-15T09:01:49.045Z"}},"version":null,"location":{"id":"0b7f16f7-9f8c-4105-b458-f98c50d360ef","name":"Atlanta, Georgia, USA","slug":"atlanta-georgia-usa","kind":"city","parentLocationId":null,"region":null,"lat":33.7544657,"lng":-84.3898151,"reviewStatus":"reviewed","aliases":[],"collisionRisk":"high","reviewNote":"Coordinates auto-geocoded on create via OpenStreetMap Nominatim (unverified; confirm before relying on map placement).","createdAt":"2026-08-08T19:00:23.021Z","updatedAt":"2026-08-09T04:26:19.821Z"},"operator":{"id":"bc532371-0bd2-47c6-9edc-7f5f701b2a24","name":"Parker Hannifin Indego","slug":"parker-hannifin-exoskeleton","description":"Parker Hannifin Indego was a division of Parker Hannifin that developed the Indego powered lower-limb exoskeleton for individuals with spinal cord injuries. Licensed from Vanderbilt University in 2012, the device received FDA clearance in March 2016 and CE Mark in November 2015, enabling users to stand and walk for up to four hours. Parker Hannifin sold the Indego business to Ekso Bionics in December 2022 for $10 million, exiting the exoskeleton market.","status":"active","founded":2012,"hq":"Cleveland, OH, USA","hqLat":41.4996574,"hqLng":-81.6936772,"hqGeocodedAt":"2026-08-05T14:43:06.985Z","hqAddress":null,"hqPrecision":null,"website":null,"fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.indego.com/","title":"Indego","date_accessed":"2026-06-07"}],"keyFacts":[{"label":"Robot","value":"Powered lower limb exoskeleton for rehabilitation and personal use"},{"label":"Products","value":"Indego Therapy and Indego Personal"},{"label":"Parent","value":"Parker Hannifin Corporation (NYSE: PH)"},{"label":"Product","value":"Indego — powered lower-limb exoskeleton"},{"label":"Use case","value":"Spinal cord injury rehabilitation, mobility assistance"},{"label":"CEO","value":"Tom Williams (Chairman & CEO of Parker Hannifin)"},{"label":"Business unit head","value":"Achilleas Dorotheou (VP, Human Motion and Control)"},{"label":"CTO","value":"Mark Czaja (Chief Technology and Innovation Officer)"},{"label":"Technology origin","value":"Licensed from Vanderbilt University (2012)"},{"label":"FDA clearance","value":"March 2016"},{"label":"CE Mark","value":"November 2015"},{"label":"Acquired by","value":"Ekso Bionics (December 2022, $10M)"},{"label":"DOD study funder","value":"CDMRP/SCIRP (4-year multi-center study)"},{"label":"Clinical trial","value":"Largest US exoskeleton clinical trial, 1,200+ sessions, no serious adverse events"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-06-08T04:05:18.726Z","updatedAt":"2026-08-15T09:01:49.045Z"},"owner":null,"derived":{"trustTier":"unverified","currentPosture":null},"jsonLd":{"@context":"https://schema.org","@type":"Event","@id":"https://registry.deploy.report/deployments/parker-indego-atlanta-georgia-usa","url":"https://registry.deploy.report/deployments/parker-indego-atlanta-georgia-usa","name":"Indego at Atlanta, Georgia, USA","identifier":"5dd7224a-4372-444b-a68d-b12f9a1ec4c4","startDate":"2014-09-01T00:00:00.000Z","location":{"@type":"Place","@id":"https://registry.deploy.report/locations/atlanta-georgia-usa","name":"Atlanta, Georgia, USA"},"organizer":{"@type":"Organization","@id":"https://registry.deploy.report/companies/parker-hannifin-exoskeleton","name":"Parker Hannifin Indego"},"about":{"@type":"Product","@id":"https://registry.deploy.report/models/parker-indego","name":"Indego"},"publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":"research","lifecycle_state":"active","architectural_position":{"cohort":"exoskeleton","sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":["primary-company-ir"]}}}